文献速递骨质疏松与代谢性骨病

地舒单抗对比双膦酸盐在既往口服双膦酸盐治疗绝经后女性中的疗效与安全性

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
PubMed 文献 · Osteoporos Int · 2019-11-28

该患者水平汇总分析纳入4项研究共2850例既往接受口服双膦酸盐的绝经后骨质疏松女性,比较换用地舒单抗60mg每6个月一次与继续双膦酸盐治疗。结果显示地舒单抗在各骨骼部位BMD提升及骨转换标志物下降均显著优于双膦酸盐,不良事件发生率相似。

要点

  • 既往口服双膦酸盐的绝经后女性换用地舒单抗安全,且BMD改善优于继续双膦酸盐。
  • 地舒单抗组腰椎、全髋、股骨颈及1/3桡骨BMD变化较双膦酸盐组高0.6%至2.0%。
  • 两组不良事件发生率相似,非典型股骨骨折仅3例。

核心结论

  • 绝经后骨质疏松女性从双膦酸盐换用地舒单抗是安全的,且改善BMD效果优于继续双膦酸盐治疗。

研究设计与样本

  • 对4项研究进行患者水平汇总分析,共纳入2850例随机患者(双膦酸盐组1424例,地舒单抗组1426例)。
  • 患者接受地舒单抗60mg每6个月一次或双膦酸盐(口服阿仑膦酸钠、利塞膦酸钠、伊班膦酸钠或静脉唑来膦酸)。

主要发现

  • 地舒单抗组各骨骼部位BMD变化均显著大于双膦酸盐组(p<0.001),差异范围为0.6%至2.0%。
  • 地舒单抗组血清CTX-1和P1NP在第1、6、12个月的下降百分比均显著大于双膦酸盐组(p<0.0001)。
  • 仅地舒单抗组第1个月血清CTX-1变化与第12个月腰椎和全髋BMD变化显著相关。
  • 两组不良事件发生率相似;3例非典型股骨骨折(双膦酸盐组1例,地舒单抗组2例),均来自地舒单抗对比唑来膦酸研究。

关键数值与推荐

  • 地舒单抗组与双膦酸盐组BMD变化差异范围为0.6%至2.0%(p<0.001)。
  • 地舒单抗组血清CTX-1和P1NP下降百分比显著大于双膦酸盐组(p<0.0001)。

临床怎么用

  • 既往口服双膦酸盐的绝经后骨质疏松女性可考虑换用地舒单抗以进一步改善BMD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate. INTRODUCTION: We conducted a patient-level pooled analysis of four studies to estimate the efficacy and safety of transitioning to denosumab vs. continuing bisphosphonate treatment in postmenopausal women who previously received oral bisphosphonates. METHODS: Patients received 60 mg denosumab once every 6 months or a bisphosphonate (oral alendronate, risedronate, ibandronate, or intravenous zoledronic acid). Endpoints were change from baseline in lumbar spine, total hip, femoral neck, and 1/3 radius BMD at month 12, change from baseline in serum CTX-1 and P1NP, and incidence of adverse events. RESULTS: A total of 2850 randomized patients (1424 bisphosphonate:1426 denosumab) were included in the analysis. Percentage change in BMD was significantly greater (p < 0.001) for denosumab vs. bisphosphonate at each skeletal site; differences in BMD changes ranged from 0.6 to 2.0%. Percentage decrease in serum CTX-1 and P1NP was significantly greater (p < 0.0001) for denosumab vs. bisphosphonate at months 1, 6, and 12; in the denosumab group only, percentage change in serum CTX-1 at month 1 was significantly correlated with percentage change in lumbar spine and total hip BMD at month 12. The incidences of adverse events were similar between treatment groups. Three patients (one bisphosphonate and two denosumab) had atypical femoral fractures, all from the denosumab vs. zoledronic acid study. CONCLUSION: Postmenopausal women can safely transition from a bisphosphonate to denosumab, which is more effective at improving BMD than continuing with a bisphosphonate. CLINICAL TRIALS REGISTRATION: NCT00377819, NCT00919711, NCT00936897, NCT01732770.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Miller PD, Pannacciulli N, Malouf-Sierra J, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2019. PMID: 31776637. doi:10.1007/s00198-019-05233-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。